Health Check: Oncosil scores rare FDA win with bile duct cancer

Oncosil Medical secured FDA approval for its bile duct cancer treatment device under the Humanitarian Device Exemption pathway, marking it as the first approved Class III device for distal cholangiocarcinoma. This approval opens a US market opportunity estimated at $80 million for treatment of inoperable, non-metastatic patients with limited survival options.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.